News
Monthly Obesity Shot Shows Big Weight Loss in Trial
At the diabetes conference, Eli Lilly presented results of a phase 1 trial of its experimental drug, eloralintide. Unlike GLP-1 drugs, it targets a hormone that slows stomach emptying. Over 12 weeks, average weight loss was 11.3%, and Lilly said gastrointestinal side effects were less common than with other drugs it has studied.
A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...
The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...
Thousand Oaks, California Wednesday, June 25, 2025, 13:00 Hrs [IST] ...
New once-a-month drug could treat diabetes and obesity, scientists say - Researchers say experimental drug’s less frequent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback